Your browser doesn't support javascript.
Reduced binding activity of vaccine serum to omicron receptor-binding domain.
Li, Mingzhi; Weng, Shiqi; Wang, Quansheng; Yang, Zibing; Wang, Xiaoling; Yin, Yanjun; Zhou, Qiuxiang; Zhang, Lirong; Tao, Feifei; Li, Yihan; Jia, Mengle; Yang, Lingdi; Xin, Xiu; Li, Hanguang; Kang, Lumei; Wang, Yu; Wang, Ting; Li, Sha; Kong, Lingbao.
  • Li M; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China.
  • Weng S; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China.
  • Wang Q; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China.
  • Yang Z; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China.
  • Wang X; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China.
  • Yin Y; GMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, China.
  • Zhou Q; Department of Clinical Laboratory, Jiangxi Provincial Children's Hospital, Nanchang, China.
  • Zhang L; Department of Clinical Laboratory, The Affiliated Hospital of Jiangxi Agricultural University, Nanchang, China.
  • Tao F; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China.
  • Li Y; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China.
  • Jia M; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China.
  • Yang L; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China.
  • Xin X; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China.
  • Li H; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China.
  • Kang L; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China.
  • Wang Y; College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, China.
  • Wang T; Center for Laboratory Animal Science, Nanchang University, Nanchang, China.
  • Li S; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China.
  • Kong L; Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China.
Front Immunol ; 13: 960195, 2022.
Article in English | MEDLINE | ID: covidwho-2071093
ABSTRACT
Coronavirus disease 2019 (COVID-19) vaccination regimens contribute to limiting the spread of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). However, the emergence and rapid transmission of the SARS-CoV-2 variant Omicron raise a concern about the efficacy of the current vaccination strategy. Here, we expressed monomeric and dimeric receptor-binding domains (RBDs) of the spike protein of prototype SARS-CoV-2 and Omicron variant in E. coli and investigated the reactivity of anti-sera from Chinese subjects immunized with SARS-CoV-2 vaccines to these recombinant RBDs. In 106 human blood samples collected from 91 participants from Jiangxi, China, 26 sera were identified to be positive for SARS-CoV-2 spike protein antibodies by lateral flow dipstick (LFD) assays, which were enriched in the ones collected from day 7 to 1 month post-boost (87.0%) compared to those harvested within 1 week post-boost (23.8%) (P < 0.0001). A higher positive ratio was observed in the child group (40.8%) than adults (13.6%) (P = 0.0073). ELISA results showed that the binding activity of anti-SARS-CoV-2 antibody-positive sera to Omicron RBDs dropped by 1.48- to 2.07-fold compared to its homogeneous recombinant RBDs. Thus, our data indicate that current SARS-CoV-2 vaccines provide restricted humoral protection against the Omicron variant.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Topics: Vaccines / Variants Limits: Child / Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.960195

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Topics: Vaccines / Variants Limits: Child / Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.960195